Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company developing antiviral therapeutics that target the replication machinery of viruses such as influenza viruses, coronaviruses, noroviruses and hepatitis C viruses. This news page compiles company announcements, press releases and regulatory disclosures so readers can follow Cocrystal’s scientific, clinical and corporate developments over time.
Visitors can review updates on CDI-988, Cocrystal’s oral pan-viral 3CL protease inhibitor being advanced as a potential prevention and treatment for norovirus infections and for coronavirus infections. Recent news has highlighted FDA Investigational New Drug (IND) clearance, a Study May Proceed Letter for a Phase 1b human challenge study, Institutional Review Board approval at Emory University School of Medicine, and previously reported favorable Phase 1 safety and tolerability data.
The feed also covers progress in the company’s influenza programs, including oral and inhaled CC-42344 for pandemic and seasonal influenza A and an influenza A/B polymerase complex program supported by a National Institutes of Health Small Business Innovation Research (SBIR) Phase I award. Articles describe human challenge studies, preclinical findings against highly pathogenic avian influenza strains and external validation through government funding.
In addition to R&D news, this page includes capital markets and corporate updates, such as registered direct offerings, private placements of common stock and warrants, and conference presentations where Cocrystal’s leadership provides company overviews and clinical progress updates. Investors and observers can use this centralized news stream to follow key milestones, including clinical trial initiations, data presentations, grant awards and financing transactions related to COCP.
Cocrystal Pharma (Nasdaq: COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of its Phase 1 study for CDI-988, an oral pan-viral norovirus/coronavirus protease inhibitor. The study, conducted in Australia, evaluated doses ranging from 100 mg to 600 mg in healthy adults. Key findings include:
- No serious adverse events or severe treatment-emergent adverse events
- No clinically significant observations in laboratory assessments, physical exams, or electrocardiograms
- All participants completed the study with no discontinuations
CDI-988 is being developed as the first dual, broad-spectrum antiviral for norovirus and coronavirus treatment. The company plans to begin multiple-ascending dose (MAD) cohorts in Q4 2024.
Cocrystal Pharma (Nasdaq: COCP) has announced that its novel antiviral, CC-42344, shows promise against the highly pathogenic avian influenza A (H5N1) strain. Recent in vitro studies indicate that CC-42344 inhibits the influenza A virus's PB2 protein, essential for replication and transcription. The drug is currently in a Phase 2a clinical trial assessing its safety, tolerability, and antiviral benefits in influenza A patients, with top-line results expected in late 2024. Previously, a Phase 1 study in healthy volunteers demonstrated favorable safety and tolerability. The company used its proprietary structure-based platform to create a high-resolution crystal structure of the avian PB2 protein, confirming CC-42344's binding efficacy. The CDC has reported recent avian flu outbreaks in the U.S., including infections in dairy cows affecting humans.
Cocrystal Pharma, Inc. (Nasdaq: COCP) reports first-quarter 2024 financial results and updates on its antiviral drug-development programs. Topline results expected for Phase 1 oral CDI-988 and Phase 2a influenza A study. FDA feedback on CC-42344, initiation of Phase 1 study for inhaled CC-42344 planned. Positive cash flow management, $21.8 million cash on hand.
Cocrystal Pharma, Inc. completes enrollment of a Phase 2a study for its oral antiviral candidate CC-42344, aiming to combat pandemic and seasonal influenza. The study evaluated safety, tolerability, and antiviral effects of the drug. The company received positive Pre-IND feedback from the FDA for a proposed Phase 2b study. Cocrystal plans to start a Phase 1 study in Australia for an inhaled formulation of CC-42344. Recent preclinical data indicates promising results for the drug.
FAQ
What is the current stock price of Cocrystal Pharma (COCP)?
What is the market cap of Cocrystal Pharma (COCP)?
